Repare Therapeutics (NASDAQ:RPTX) Shares Gap Up to $11.88

Repare Therapeutics Inc. (NASDAQ:RPTXGet Rating) gapped up prior to trading on Wednesday . The stock had previously closed at $11.88, but opened at $12.55. Repare Therapeutics shares last traded at $12.53, with a volume of 15 shares trading hands.

Analysts Set New Price Targets

RPTX has been the topic of several research analyst reports. Piper Sandler upped their target price on Repare Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, June 2nd. Stifel Nicolaus lowered Repare Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, April 12th. Finally, HC Wainwright cut their target price on Repare Therapeutics from $54.00 to $38.00 and set a “buy” rating on the stock in a research report on Monday, June 6th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.71.

Repare Therapeutics Stock Up 5.0 %

The stock has a market capitalization of $550.07 million, a PE ratio of -4.28 and a beta of -0.23. The firm has a 50 day moving average price of $13.42 and a 200 day moving average price of $13.07.

Repare Therapeutics (NASDAQ:RPTXGet Rating) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.06. The firm had revenue of $0.41 million during the quarter, compared to the consensus estimate of $2.13 million. Repare Therapeutics had a negative return on equity of 47.60% and a negative net margin of 1,533.38%. On average, equities analysts forecast that Repare Therapeutics Inc. will post -3.35 earnings per share for the current fiscal year.

Insider Transactions at Repare Therapeutics

In related news, major shareholder Bvf Partners L. P/Il acquired 6,869 shares of the stock in a transaction dated Monday, June 6th. The stock was purchased at an average cost of $13.21 per share, with a total value of $90,739.49. Following the completion of the purchase, the insider now directly owns 4,368,757 shares in the company, valued at approximately $57,711,279.97. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. In other Repare Therapeutics news, major shareholder Bvf Partners L. P/Il purchased 6,869 shares of the company’s stock in a transaction that occurred on Monday, June 6th. The shares were acquired at an average cost of $13.21 per share, for a total transaction of $90,739.49. Following the completion of the acquisition, the insider now owns 4,368,757 shares of the company’s stock, valued at approximately $57,711,279.97. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bvf Partners L. P/Il purchased 420,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 18th. The shares were acquired at an average price of $8.50 per share, for a total transaction of $3,570,000.00. Following the completion of the acquisition, the insider now directly owns 3,350,950 shares of the company’s stock, valued at approximately $28,483,075. The disclosure for this purchase can be found here. Insiders purchased a total of 1,762,075 shares of company stock valued at $19,412,565 over the last ninety days. 33.60% of the stock is currently owned by insiders.

Institutional Trading of Repare Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Redmile Group LLC lifted its holdings in Repare Therapeutics by 8.6% during the fourth quarter. Redmile Group LLC now owns 2,789,496 shares of the company’s stock worth $58,830,000 after acquiring an additional 221,800 shares during the period. Deep Track Capital LP raised its stake in shares of Repare Therapeutics by 26.9% in the first quarter. Deep Track Capital LP now owns 2,664,017 shares of the company’s stock valued at $37,936,000 after buying an additional 564,017 shares during the period. Affinity Asset Advisors LLC raised its stake in shares of Repare Therapeutics by 72.5% in the first quarter. Affinity Asset Advisors LLC now owns 468,905 shares of the company’s stock valued at $6,677,000 after buying an additional 197,127 shares during the period. BlackRock Inc. raised its stake in shares of Repare Therapeutics by 1.9% in the first quarter. BlackRock Inc. now owns 467,311 shares of the company’s stock valued at $6,655,000 after buying an additional 8,680 shares during the period. Finally, Sectoral Asset Management Inc. raised its stake in shares of Repare Therapeutics by 15.0% in the first quarter. Sectoral Asset Management Inc. now owns 237,785 shares of the company’s stock valued at $3,386,000 after buying an additional 31,000 shares during the period. 89.66% of the stock is currently owned by institutional investors.

Repare Therapeutics Company Profile

(Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Featured Articles

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.